Spots Global Cancer Trial Database for alisertib
Every month we try and update this database with for alisertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | NCT02812056 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Alisertib TAK-228 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | NCT06095505 | Small Cell Lung... | Alisertib | 18 Years - | Puma Biotechnology, Inc. | |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 | Advanced Solid ... Ovarian Cancer Small Cell Lung... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | NCT01695941 | Recurrent B-Cel... Recurrent Mantl... Refractory B-Ce... Refractory Mant... | Alisertib Bortezomib Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | NCT01844583 | Solid Tumors Lymphoma | Alisertib Esomeprazole Rifampin | 18 Years - | Takeda | |
| Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors | NCT02319018 | Malignant Diges... | Alisertib Fluorouracil Laboratory Biom... Leucovorin Calc... Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01812005 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | alisertib rituximab laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | NCT01094288 | Advanced Solid ... Adenocarcinoma ... | Alisertib Docetaxel | 18 Years - | Takeda | |
| A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | NCT00830518 | Acute Myelogeno... High-Grade Myel... | Alisertib | 18 Years - | Takeda | |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | NCT04555837 | Head and Neck S... Malignant Solid... | Alisertib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | NCT01923337 | Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IIIA Colo... Unspecified Adu... | irinotecan hydr... alisertib | 18 Years - | University of California, Davis | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | NCT04479306 | Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alisertib Osimertinib Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | NCT00853307 | Ovarian Carcino... | Alisertib | 18 Years - | Takeda | |
| Alisertib for Acute Myeloid Leukemia | NCT01779843 | Acute Myelogeno... | Cytarabine Idarubicin Alisertib | 18 Years - | Massachusetts General Hospital | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | NCT01848067 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | Alisertib Abiraterone ace... Prednisone | 18 Years - | Thomas Jefferson University | |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| Study of MLN8237 in Participants With Advanced Solid Tumors | NCT00962091 | Advanced Solid ... | Alisertib | 18 Years - | Takeda | |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | NCT01653028 | Myxofibrosarcom... Recurrent Adult... Recurrent Leiom... Recurrent Lipos... Recurrent Malig... Recurrent Undif... Stage III Soft ... Stage IV Soft T... | Alisertib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | NCT06369285 | Hormone Recepto... Metastatic Brea... Recurrent Breas... | Alisertib Endocrine thera... | 18 Years - | Puma Biotechnology, Inc. | |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | NCT04085315 | Lung Cancer Met... EGFR Gene Mutat... | Osimertinib Alisertib | 18 Years - | University of California, San Francisco | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT01637961 | Recurrent Uteri... Uterine Corpus ... | Alisertib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | NCT01639911 | Malignant Neopl... CNS Malignancy Malignant Neopl... Genitourinary N... Head and Neck N... Melanoma Malignant Neopl... | Alisertib Pazopanib | 18 Years - | University of Illinois at Chicago | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | NCT02187991 | Breast Cancer Breast Carcinom... Breast Tumors Malignant Neopl... | Paclitaxel Alisertib | 18 Years - | US Oncology Research | |
| Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | NCT02186509 | Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Diffuse A... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Oligodend... Adult Pilocytic... Adult Pineal Gl... Adult Subependy... Recurrent Adult... | Hyperfractionat... Stereotactic ra... Alisertib Quality-of-life... | 18 Years - | Thomas Jefferson University | |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | NCT01897012 | MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu... | Alisertib Laboratory Biom... Romidepsin | 18 Years - | National Cancer Institute (NCI) | |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | NCT01848067 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | Alisertib Abiraterone ace... Prednisone | 18 Years - | Thomas Jefferson University | |
| Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | NCT02293005 | Lung Cancer Mesothelioma | Alisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | NCT01091428 | Ovarian Carcino... Fallopian Tube ... Peritoneal Canc... Breast Carcinom... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors | NCT00500903 | Advanced Malign... | Alisertib | 18 Years - | Takeda | |
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | NCT01482962 | Relapsed Periph... Refractory Peri... | Alisertib Pralatrexate Gemcitabine Romidepsin | 18 Years - | Takeda | |
| Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | NCT01714947 | Advanced Solid ... Lymphoma | [^14C]-aliserti... alisertib | 18 Years - | Takeda | |
| A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors | NCT00500903 | Advanced Malign... | Alisertib | 18 Years - | Takeda | |
| Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | NCT04479306 | Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alisertib Osimertinib Sapanisertib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | NCT02700022 | Diffuse Large B... Follicular Lymp... Burkitt Lymphom... | Alisertib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | NCT01898078 | Advanced Solid ... Lymphoma | Alisertib | 18 Years - | Takeda | |
| Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT01637961 | Recurrent Uteri... Uterine Corpus ... | Alisertib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | NCT02038647 | Small Cell Lung... | Alisertib Placebo Paclitaxel | 18 Years - | Takeda | |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | NCT04555837 | Head and Neck S... Malignant Solid... | Alisertib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
